$MLTX News
Last published 1w ago
- 1w agoMLTXMoonLake Immunotherapeutics - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoMLTXMoonLake Reports Third Quarter 2026 Financial Results and Provides a Business UpdateGlobeNewswireBiologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, marking an important step
- 3mo agoMLTXMoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial ResultsGlobeNewswirePhase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and
- 4mo agoMLTXMoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public OfferingGlobeNewswireZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases,
- 4mo agoMLTXMoonLake Immunotherapeutics Announces Proposed Public OfferingGlobeNewswireZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases,
- 4mo agoMLTXMoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026GlobeNewswireResults from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with
- 6mo agoMLTXMoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial ResultsGlobeNewswireMoonLake conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA), where MoonLake and the FDA aligned on submission plans and the label strategy for
- 7mo agoMLTXMoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual MeetingGlobeNewswireResults from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab
- 8mo agoMLTXMoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial ResultsGlobeNewswireIn the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12Consistently, other clinical and
- 9mo agoIMAMLTXImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical OfficerGlobeNewswireBrings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase
- 9mo agoMLTXMoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor DayGlobeNewswireThe Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positive results from the
- 10mo agoACONFLYXKBLBMLTXMorning Market Pulse: From Orbit to Biomaterials, Innovation Drives the TapeGlobeNewswireDENVER, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Markets head into the session with a familiar but powerful theme in focus: enabling technologies that quietly unlock the next wave of growth. From satellite connectivity at
- 10mo agoMLTXMoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor DayGlobeNewswireMoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application (BLA) for
- 11mo agoMLTXThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTXPR NewswireThe Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of...
- 11mo agoMLTXMoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – MLTXGlobeNewswireNEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ:MLTX). Shareholders who purchased shares of MLTX during the class
- 11mo agoMLTXInvestors in MoonLake Immunotherapeutics Should Contact The Gross Law Firm Before December 15, 2025 to Discuss Your Rights – MLTXGlobeNewswireNEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ:MLTX). Shareholders who purchased shares of MLTX during the class
- 11mo agoMLTXMoonLake Immunotherapeutics Sued for Securities Law Violations - Contact The Gross Law Firm Before December 15, 2025 to Discuss Your Rights - MLTXPR NewswireThe Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of...
- 11mo agoMLTXUPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake" or the...
- 11mo agoMLTXMLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 11mo agoMLTXMoonLake Immunotherapeutics Sued for Securities Law Violations - Contact The Gross Law Firm Before December 15, 2025 to Discuss Your Rights - MLTXPR NewswireThe Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of...
- 1y agoMLTXMoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten OfferingGlobeNewswireZUG, Switzerland, November 5, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on advancing therapies to address significant unmet needs in inflammatory skin
- 1y agoMLTXMoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® SonelokimabGlobeNewswireEnded the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to provide runway into
- 1y agoMLTXMLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In MoonLake To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoMLTXSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 1y agoMLTXSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake" or the...
- 1y agoMLTXMLTX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options If you suffered significant
- 1y agoMLTXMoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm's InvestigationGlobeNewswireBOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MoonLake Immunotherapeutics (NASDAQ:MLTX) for potential securities law violations. Investors who have lost money in their MoonLake
- 1y agoMLTXMLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options If you suffered significant
- 1y agoMLTXBREAKING: MoonLake Immunotherapeutics Shares Down Over 85%; Investors Should Contact Block & Leviton to Potentially Recover LossesGlobeNewswireBOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential securities law violations.
- 1y agoMLTXMoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimabGlobeNewswire
- 1y agoMLTXMoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business UpdateGlobeNewswirePhase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in
- 1y agoHTGCMLTXMoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business UpdateGlobeNewswireMoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of
- 1y agoMLTXMoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29GlobeNewswireMoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biotechnology company focused on creating
- 1y agoHTGCMLTXMoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical UpdatesGlobeNewswireAgreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to shareholders, an attractive cost of capital and low operational and
- 1y agoMLTXMoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business UpdateGlobeNewswireInitiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic arthritis (PsA)
- 1y agoMLTXMoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimabGlobeNewswireNew trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosis (PPP)
- 1y agoCGEMCRGXDCTHELVN+8Clear Street Launches Healthcare & Biotechnology Equity ResearchBusiness WireComprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a
- 1y agoMLTXMoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisGlobeNewswireMoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on biologic-naïve
- 2y agoMLTXMoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewswireMoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable debt securities,
- 2y agoMLTXMoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11GlobeNewswireMoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (("MoonLake", NASDAQ:MLTX), a clinical-stage biotechnology
- 2y agoMLTXMoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11GlobeNewswireMoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody® sonelokimab in hidradenitis
- 2y agoMLTXMoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic ArthritisGlobeNewswireMoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis Builds upon the positive regulatory
- 2y agoMLTXMoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativaGlobeNewswireMoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa VELA is the first Phase 3 program in hidradenitis suppurativa to
- 2y agoMLTXMoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewswireMoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the
- 2y agoMLTXMoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditionsGlobeNewswireMoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions MoonLake to tap into Komodo's technology and real-world data to unlock
- 2y agoMLTXMoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint ConditionsBusiness WireMoonLake To Tap Into Komodo's Technology and Real-World Data To Unlock the Full Potential of Its Next-Gen Nanobody® Therapy MoonLake Immunotherapeutics (("MoonLake", NASDAQ:MLTX), a clinical-stage biotechnology
- 2y agoMLTXMoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D DayGlobeNewswireMoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from the ARGO trial of
- 2y agoMLTXMoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024GlobeNewswireMoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 ZUG, Switzerland, March 4, 2024 – MoonLake
- 2y agoMLTXMoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10GlobeNewswireMoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 A successful year including the announcements of positive data from two Phase 2
- 2y agoMLTXMoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)GlobeNewswireMoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS) Clarified path for HS